Inflammasome Therapeutics的动态

Throwback Thursdays: Q1 2022 Hillhurst manufactured HBI-002 drug product in preparation for our phase 1 clinical trial in healthy subjects. HBI-002 is an oral investigational drug product for the treatment of Sickle Cell Disease, designed to deliver low targeted doses of carbon monoxide. Both clinical and preclinical studies with inhaled low dose carbon monoxide support a potential therapeutic role in SCD. However, up to now, no one has ever attempted to deliver CO through the stomach. For the first time we were about to test whether patients can obtain the same beneficial low levels of CO (5% - 10% blood concentration) through the gut.

???????????????????? ???????? ???????????????????????? ???????????? ???????? ?????? ???? ?????? ?????????????? ?????? ????????????? ?????????? ???? ?????????? BrainStorm Cell Therapeutics (NASDAQ: BCLI) Brainstorm Cell Therapeutics has reached alignment with the FDA on the Chemistry, Manufacturing, and Controls (CMC) aspects of its Phase 3b trial for NurOwn?, its investigational therapy for ALS. This follows the positive momentum from April 2024, when the FDA granted BrainStorm a Special Protocol Assessment (SPA) agreement, providing clarity on the trial's design and endpoints. "This in-person Type C meeting with the FDA was crucial as we finalize preparations for our pivotal Phase 3b trial of NurOwn. We are very pleased with the outcome and are now aligned on resolving all previously outstanding CMC questions," said Chaim Lebovits Chaim Lebovits, President & CEO of BrainStorm. "We are committed to working closely with the FDA and are excited to move forward with the Phase 3b trial to address the unmet needs of ALS patients." #ALS #StemCellTherapy #ClinicalTrials #FDA #NurOwn #BrainStormCellTherapeutics #Biotech #NeurodegenerativeDiseases

EEV? therapeutics consist of two essential parts: an EEV and a therapeutic modality. We’re working to establish a new class of medicines with the potential to reach and engage disease-causing targets within cells. ? Curious #HowWeEEV? Get the facts: https://lnkd.in/dcFuBP5F

Thoughts on this? >> Novartis expands Scemblix label to first-line CML patients >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #pharma #biotech #productmarketing #healthcare

Thoughts on this? >> Novartis expands Scemblix label to first-line CML patients >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #biotech #pharmaceutical #pharma #healthcare

With the approval of OGSIVEO? (nirogacestat), patients must contact their healthcare provider to see if the drug is right for them. SpringWorks Therapeutics, the pharmaceutical company that developed the drug, has several resources available to desmoid tumor patients. ?? SpringWorks Therapeutics has a patient support services program called SpringWorks CareConnections? for people prescribed OGSIVEO? (nirogacestat). Physicians and patients can contact 1-844-CARES-55 (1-844-227-3755) or visit springworkstxcares.com. This is a free, personalized patient support program to help navigate insurance coverage, answer questions about treatment, and help patients start and stay on track with OGSIVEO? (nirogacestat). ?? Official website: Ogsiveo.com ?? Official Facebook page: facebook.com/OGSIVEO ?? Official Facebook group for health care providers: facebook.com/ogsiveoHCP #Desmoid #DesmoidTumors #DesmoidTumor #fibromatosis #aggressivefibromatosis #DTRF #DesmoidTumorResearchFoundation #Desmoidian #desmoidresearch #FAP #familialadenomatouspolyposis #OrphanDisease #raredisease #oncology #research #hope #OGSIVEO #nirogacestat #expandedaccess

?? Kicking off Day 2 of the 20th BioPharma Drug Discovery Nexus Conference with a bang! Join Mauro Mileni Founder and CEO, Abilita Therapeutics, Inc. as he unveils insights into 'Enabling the Discovery of Therapeutic Antibodies Targeting Challenging Membrane Proteins'. Don't miss out on this enlightening session! #BioPharma #DrugDiscovery #Innovation #Antibodies #Therapeutics #Membraneproteins #Epitopes #Conformational #Protiens #NexusConference #SanDiego #USconference #ScientificConference

The European Medicines Agency’s 2023 annual report showcases advances in cancer drug development, data-driven medicine regulation, and transparency, including the approval of two RSV vaccines and the first CRISPR/Cas9 therapy. #gmdpacademy #medicalaffairs #medicinesdevelopment #pharma #clinicaltrials #genetherapy #healthinnovation https://bit.ly/4dyaqj0

AbbVie’s $8.7 Billion Cerevel Buy Starts to Pay Off with Phase III Parkinson’s Win AbbVie has announced that its investigational Parkinson’s disease drug tavapadon met its primary efficacy endpoint in the Phase III TEMPO-1 trial, showing significant improvements in motor and non-motor symptoms in patients with early-stage disease. Tavapadon was originally developed by Cerevel Therapeutics, which AbbVie acquired for $8.7 billion in December 2023. The companies formally completed the deal last month. AbbVie is also running the TEMPO-4 trial, which will assess the long-term safety and tolerability of tavapadon, and the TEMPO-2 study, which is looking at a flexible-dose regimen of tavapadon monotherapy. Topline data from the latter study are set to come out by the end of 2024. https://lnkd.in/ghki4BsY #aspenalert #biotech #bioprocess

Today Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) shared an exciting analysis of a clinical trial conducted by Abbott supporting our belief that Cadrenal's lead drug candidate tecarfarin could be an important next-generation anticoagulant for patients with LVADs. Quoted in the news release lead investigator of the trial, Dr. Mandeep Mehra, states,?"…Tecarfarin could potentially be an important therapy for patients with LVADs who all require chronic anti-coagulation since it does not get affected by drug-drug interactions or changes in kidney function like warfarin and deserves further study." Read more: https://lnkd.in/gypE4XZc ? #cadrenal #nasdaq #cvkd #therapeutics #tecarfarin Quang Pham Matthew Szot